Cellusion has been selected to NEDO STS program 2019

TOKYO (JUNE 12, 2019)-, Cellusion Inc. (Headquarters, Tokyo; CEO: Shin Hatou, M.D., Ph.D., “Cellusion”) announced the New Energy and Industrial Technology Development Organization (NEDO) has selected Cellusion to seed-stage technology-based startups (STS) program 2019. Keio Innovation Initiative, Inc. (KII) as the certified venture capital and NEDO support Cellusion to conduct pre-clinical proof of concept study on induced pluripotent stem cell-derived corneal endothelial cells for bullous keratopathy therapy. Cellusion is hopeful that this support will accelerate to deliver novel therapies for all bullous keratopathy patients.

See details: https://www.nedo.go.jp/koubo/CA3_100199.html
For further information: please ask us through contact form in our website.

<About Keio Innovation Initiative, Inc.>
Keio Innovation Initiative, Inc. is a venture capital group based in Keio University. Our mission is to help create new industries and contribute to the development of society through investments in startups that harness the research achievements made by Keio University to create innovative new businesses.

Company ：Keio Innovation Initiative, Inc.
CEO ：Kotaro Yamagishi
Headquarter ：1-4-28 Mita, Minato, Tokyo 108-0073, JAPAN
Founded ： December 2015
URL ： https://www.keio-innovation.co.jp/

<About Cellusion Inc.>
Cellusion Inc. is a regenerative medicine startup from Keio University. The mission of Cellusion is to deliver novel therapies for all bullous keratopathy patients by our iPS cells origin corneal endothelial cells mass culture system.

Company ： Cellusion Inc.
CEO ： Shin Hatou, M.D., Ph.D.
Headquarter ：2-4-15 Minamiaoyama, Minato, Tokyo 107-0062, JAPAN
Founded ： January 2015
URL ： https://cellusion.jp/